An observational study in Myocardial Infarction, sponsored by Osama Fekry. Status unknown at 1 site in Egypt. Open to participants aged Up to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-12.
Sponsored by Osama Fekry · Observational
is to test the hypotheses that epicardial adipose tissue can be a marker of severity of coronary artery disease in myocardial infarction patients
epicardial adipose tissue is defined as the adipose tissue between the visceral pericardium and the outer margin of the myocardium which can be considered an endocrine organ that secretes pro-inflammatory and anti-inflammatory cytokines and chemokines including adiponectin.as investigators know, inflammatory response is an important factor in the coronary atherogenesis. Therefore,epicardial adipose tissue is likely to be connected with the severity of coronary artery disease.Recent studies showed that the thickness of the epicardial adipose tissue in patients with coronary artery disease was greater than that with normal coronary arteries.
epicardial adipose tissue will be assessed using transthoracic echocardiography and cardiac magnetic resonance which allows for an accurate volumetric quantification of epicardial fat.
acute myocardial infarction patiens not previously underwent percutaneous coronary angiography or coronary artery bypass grafting
Exclusion Criteria:
transthoracic echocardiography and cardiac magnetic resonance
Radiation: echocardiography and cardiac magnetic resonance
transthoracic echocardiography and magnetic resonance imaging of the heart
measurement of epicardial adipose tissue as marker of severity of coronary artery disease in myocardial infarction patients.
epicardial adipose tissue measurement using transthoracic echocardiography and cardiac magnetic resonance
Time frame: one year
This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.